Anti-dopamine D2 receptor antibodies in chronic tic disorders

EMTICS Collaborative Grp, Addabbo, F., Baglioni, V., Schrag, A., Schwarz, M. J., Dietrich, A., Hoekstra, P. J., Martino, D. & Buttiglione, M., 9-Jul-2020, In : Developmental Medicine and Child Neurology. 62, 10, p. 1205-1212 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard


  • Anti‐dopamine D2 receptor antibodies in chronic tic disorders

    Final publisher's version, 2.05 MB, PDF document

    Request copy


Aim To investigate the association between circulating anti-dopamine D2 receptor (D2R) autoantibodies and the exacerbation of tics in children with chronic tic disorders (CTDs). Method One hundred and thirty-seven children with CTDs (108 males, 29 females; mean age [SD] 10y 0mo [2y 7mo], range 4-16y) were recruited over 18 months. Patients were assessed at baseline, at tic exacerbation, and at 2 months after exacerbation. Serum anti-D2R antibodies were evaluated using a cell-based assay and blinded immunofluorescence microscopy scoring was performed by two raters. The association between visit type and presence of anti-D2R antibodies was measured with McNemar's test and repeated-measure logistic regression models, adjusting for potential demographic and clinical confounders. Results At exacerbation, 11 (8%) participants became anti-D2R-positive ('early peri-exacerbation seroconverters'), and nine (6.6%) became anti-D2R-positive at post-exacerbation ('late peri-exacerbation seroconverters'). The anti-D2R antibodies were significantly associated with exacerbations when compared to baseline (McNemar's odds ratio=11,p=0.003) and conditional logistic regression confirmed this association (Z=3.49,p

Original languageEnglish
Pages (from-to)1205-1212
Number of pages8
JournalDevelopmental Medicine and Child Neurology
Issue number10
Publication statusE-pub ahead of print - 9-Jul-2020



ID: 129631921